Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) on March 15, 2028. There are 2 upcoming events on record.
| Date | Event | Type | Phase |
|---|---|---|---|
| March 15, 2028 | Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Trial Milestone | Phase 2/Phase 3 |
| June 15, 2028 | A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) | Trial Milestone | Phase 1 |
Track ETRA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ETRA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 21, 2026 | 8-K filed: Other event | Filing | — |
| November 20, 2023 | Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.